International Stem Cell Corporation (ISCO.ob) is a California biotechnology company focused on developing therapeutic and research products. ISCO’s technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists also have created the first Parthenogenic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will not be immune rejected after transplantation into millions of individuals of differing sexes, ages and racial groups. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. - (Read more)

Athersys (Nasdaq: ATHX) is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics designed to treat significant and life-threatening diseases. The Company's lead programs are in the areas of obesity, cardiovascular disease (myocardial infarction), and bone marrow transplant support.   - (Read more)

Geron (Nasdaq: GERN) is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. - (Read more)

StemCells, Inc. (Nasdaq: STEM) is focused on the discovery and development of stem cell therapeutics to treat damage to or degeneration of major organ systems such as the Central Nervous System, Liver and Pancreas. - (Read more)

Stem Cell Regeneration For Wounded Bulls (AMGN, CELG, KOOL, STEM)

It seems as if almost no sector is safe in the present market, but for investors who are looking for long-term value/growth plays, the recent selloff may have opened significant opportunity within stem cell stocks.

[Read more]